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Abstract
Background: High-density Lipoprotein (HDL) attenuates endothelial cell apoptosis induced by different cell-death
stimuli such as oxidation or growth factor deprivation. HDL is the main plasma carrier of the bioactive lipid sphingosine
1-phosphate (S1P), which it is a signaling molecule that promotes cell survival in response to several apoptotic stimuli.
In HDL, S1P is bound to Apolipoprotein M (ApoM), a Lipocalin that is only present in around 5% of the HDL particles.
The goal of this study is to characterize ApoM-bound S1P role in endothelial apoptosis protection and the signaling
pathways involved.
Methods: Human umbilical vein endothelial cells (HUVEC) cultures were switched to serum/grow factor deprivation
medium to induce apoptosis and the effect caused by the addition of ApoM and S1P analyzed.
Results: The addition of HDL+ApoM or recombinant ApoM-bound S1P promoted cell viability and blocked apoptosis,
whereas HDL-ApoM had no protective effect. Remarkably, S1P exerted a more potent anti-apoptotic effect when carried
by ApoM as compared to albumin, or when added as free molecule. Mechanistically, cooperation between S1P1 and
S1P3 was required for the HDL/ApoM/S1P-mediated anti-apoptotic ability. Furthermore, AKT and ERK phosphorylation
was also necessary to achieve the anti-apoptotic effect of the HDL/ApoM/S1P complex.
Conclusions: Altogether, our results indicate that ApoM and S1P are key elements of the anti-apoptotic activity of HDL
and promote optimal endothelial function.
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Highlights
 ApoM-bound S1P and ApoM-containing HDL are
anti-apoptotic.
 HDL/ApoM/S1P complex signals through S1P1 and
S1P3.
 ApoM-bound S1P anti-apoptotic effect is more po-
tent than albumin-bound S1P.
Background
Apolipoprotein M (ApoM) is a member of the Lipocalin
family and its structure is defined by an eight-stranded
antiparallel β-barrel enclosing a hydrophobic binding
pocket, where different ligands bind, e.g. retinol [1], oxi-
dized phospholipids [2] and sphingosine 1-phosphate
(S1P) [3]. Out of these, S1P is the only ApoM-ligand
known to bind in vivo. An unusual property of ApoM is
that its signal peptide is not cleaved off during secretion
and used by the mature ApoM protein to anchor the
protein to the phospholipid bilayer of high-density lipo-
proteins (HDL) [4, 5]. The plasma concentration of
ApoM is approximately 0.9 μM and around 5% of all
HDL particles in circulation carry ApoM and S1P [6, 7].
ApoM is the major carrier of S1P in circulation (~65%),
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the remaining S1P in plasma being bound to albumin
(~35%) [7].
Sphingolipids have multiple key physiological func-
tions that are important for the regulation of cell growth
and survival. Ceramide and sphingosine are inducers of
growth arrest and apoptosis and many stress stimuli in-
crease the cellular levels of these compounds. In
contrast, S1P is associated with suppression of apoptosis
[8, 9].Five different membrane-bound, G-protein
coupled S1P receptors (S1PR, S1P1-5) are known and
binding of S1P to these receptors activates multiple
receptor-specific downstream signaling pathways. In this
way, S1P is able to regulate several biologic processes,
such as immune cell trafficking, angiogenesis, cell migra-
tion and cell survival [10]. Indeed, S1PR represent import-
ant drug therapeutic targets. For instance, FTY720,
also known as Fingolimod, is phosphorylated by en-
dogenous kinases and works as a functional antagon-
ist of S1P1 that has been approved for the treatment
of multiple sclerosis [11].
The integrity of endothelial cells lining the vessels is
crucial for vascular homeostasis and endothelial cell-
death triggers vascular leakage and promotes inflamma-
tion in adjacent tissues [12]. Additionally, apoptotic
endothelial cells become pro-coagulant and may provoke
formation of blood clots [13]. Thus, increased endothe-
lial cell apoptosis is associated with several cardiovascu-
lar pathologies, in particular with thrombosis and
atherosclerosis [14].
HDL particles are potently anti-atherogenic and reduce
endothelial cell apoptosis [15, 16]. Cholesterol efflux is one
of the mechanisms underlying HDL protection of endothe-
lium, and importantly, ApoM-containing HDL enhances
cholesterol efflux [17, 18]. Likewise, it is known that free
S1P attenuates apoptosis in endothelial cells [15, 19]. The
goal of the present study was to further characterize the
role of S1P in the regulation of human endothelial cell
apoptosis and to define the signaling pathways involved.
For that purpose, we took into account that HDL-
associated S1P is bound to ApoM in plasma. We have used
human ApoM-containing HDL (HDL+ApoM) and
ApoM-lacking HDL (HDL-ApoM) to study regulation
of apoptosis in human endothelial cells. Moreover, we
have elucidated whether the anti-apoptotic properties
of S1P are carrier dependent by comparing the anti-
apoptotic effects of albumin-bound S1P, ApoM-bound
S1P and S1P as a free molecule.
Methods
Cell culture and apoptosis induction
Human Umbilical Vein Endothelial Cells (HUVEC) were
obtained from Gibco, grown in 1% gelatin pre-coated
plates in M200 medium containing 1% penicillin and
streptomycin and low serum growth supplement (LSGS)
(all from Gibco) at 37 °C in a humidified 5% CO2 incu-
bator. The culture medium was replaced every 2 days,
and cells were subcultured at 90–95% confluence. Cells
were studied between passages 2–8.
LSGS contains fetal bovine serum (FBS), human epi-
dermal growth factor (EGF), basic fibroblast growth fac-
tor (bFGF), heparin and hydrocortisone. Removal of all
these components was used to induce apoptosis in
HUVEC. This treatment will be referred as serum/GF
deprivation. For that, cells were washed twice with
M200 medium without LSGS. The absence of S1P in
M200 medium without LSGS was verified by mass spec-
trometry as it was previously described in [7, 20].
Purifications (ApoM and HDL)
Recombinant soluble human ApoM (residues 22–188,
without the signal peptide, Swiss-Prot entry O95445)
was expressed in E. coli, purified from inclusion bodies
and refolded as described in Ahnström et al. [1]. ApoM
binding to S1P was confirmed by intrinsic fluorescence
quenching and isoelectric focusing as described in Sev-
vana et al. [3]. ApoM loading with S1P was performed
as in Ruiz et al.[21].
HDL was isolated from human plasma obtained from
the Blood Bank at Växjö Hospital, Sweden, as described
in Ruiz et al. [21]. Briefly, HDL were separated by ultra-
centrifugation followed by size exclusion chromatog-
raphy. HDL+ApoM and HDL-ApoM were isolated by
immunoaffinity chromatography with M23 and M58
monoclonal antibodies against ApoM.
S1P levels in HDL preparations were quantified by
mass spectrometry as it was previously described [7, 20].
S1P was ~0.146 μM/mg protein in total HDL,
~0.417 μM/mg of protein in HDL+ApoM and ~0.008 μM/
mg protein in HDL-ApoM.
Protein quantification, protein electrophoresis and
western blot
Sample protein concentration was quantified using BCA
protein assay kit (Pierce) according manufacturer’s
instructions.
Electrophoresis was done in 4–15% gradient pre-casted
SDS-gels (Bio-Rad) under reducing conditions. Western
blotting was done after separation in a Trans-Blot Turbo
transfer system (Bio-Rad). An Antibody against phospho-
ERK1 (T202/Y204) / phospho-ERK2 (T185/Y187) ERK1/2
was from R&D systems; antibodies against total ERK
(#9102), pSer473 AKT (D9E), total AKT (C67E7) were
from Cell Signaling and an antibody against GAPDH was
from Santa Cruz Biotechnology (#20357).
Annexin V staining and flow cytometry
Cells were detached with TrypLE Express (Gibco),
washed and resuspended in Annexin V binding buffer
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(BD Bioscience). Then, cells were stained with PE
Annexin V and 7-ADD according manufacturer’s in-
structions (BD Bioscience) and analyzed in a Cytomics
FC500 (Beckman Coulter) flow cytometer. Data were an-
alyzed with FlowJo X v.10.0 7r2. Early apoptotic cells
were defined by Annexin V+ and 7-ADD−.
Measurement of caspase-3 activity
Caspase-3 activity was measured using a colorimetric
assay kit according to manufacturer’s instructions
(Abcam). Briefly, cell lysates (50 μg total protein) were
incubated in the presence of N-acetyl-Asp-Glu-Val-Asp-
p-nitroanilide (Ac-DEVD-pNA, 200 μM) and the release
of pNA was measured using a plate reader (TECAN In-
finite F200) at 405 nm.
Cell viability assay
Cell viability was evaluated by the MTT assay following
manufacturer’s instructions (Roche). Briefly, viable cells
are defined by their ability to reduce MTT (3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) to
formazan, which is a measure of an active metabolism.
The conversion was quantified using a plate reader
(TECAN Infinite F200) at 570 nm and optical density
value was utilized as an indicator of cell viability.
Quantitative real-time PCR (qPCR)
Total cellular RNA was isolated using RNeasy Kit ac-
cording to the manufacturer’s instructions (Qiagen) and
quantified using a NanoDrop spectrophotometer
(ND2000, Thermo Scientific). qPCR were performed
with a CFX384 C1000 thermal cycler (Bio-Rad) using
the Super Scrip III Platinum One Step qRT-PCR kit
(Invitrogen) and TaqMan probes (Applied Biosystems):
4326317E (GAPDH), Hs00173499_m1 (S1P1), AJ39RQ5
(S1P2), Hs00245464_s1 (S1P3), Hs02330084_s1 (S1P4)
and Hs00928195_s1 (S1P5) according manufacturer’s in-
structions. Samples were measured as quadruplicates.
The relative expression of each gene was calculated ac-
cording to the ΔΔCT method [22]. Expression of the
housekeeping gene GAPDH was used to normalize for
variations in RNA input.
Other reagents
Sphingosine-1-Phosphate (d18:1; Lipid Maps LMSP01
050001) was purchased from Avanti Polar Lipids and
Sigma; bovine fatty acid free albumin was from Sigma;
W146, CAY10444 and ML-031 were from Cayman
Chemical; SEW2871 and CYM5541 were from Tocris
Bioscience; LY294002, U0126 and PD98059 were from
R&D systems.
Statistical analysis
Statistical analyses were performed with SigmaPlot 11.0
software (Systat Software Inc.). A value of p < 0.05 was
defined as threshold for significant changes. Student t-test
and Mann-Whitney U-test were used for two-sample
comparisons and ANOVA was used when assaying for
multiple comparisons. The particular tests used for post
hoc analyses depended on homoscedasticity, and are
stated in the figure legends.
Results
HDL+ApoM protects endothelial cells against apoptosis and
promotes cell survival
Endothelial cells undergo apoptosis when deprived of
serum and growth factors (Fig. 1a) [15, 16, 23]. However,
HDL addition to the cell medium mitigates serum/GF
deprivation induced cell death [15, 16]. To assess the role
of ApoM and S1P in HDL mediated protection we iso-
lated HDL+ApoM and HDL-ApoM. Then, HUVEC were
serum/GF deprived in the presence of HDL+ApoM or
HDL-ApoM for 18 h and the amount of apoptotic cells
measured by flow cytometry. HDL+ApoM reduced the per-
centage of apoptotic cells, whereas HDL-ApoM did not
confer any protection against serum/GF deprivation
(Fig. 1b and c). Consistently, total HDL also protected
HUVEC against serum/GF deprivation (Fig. 1d). To con-
firm the anti-apoptotic effect of HDL+ApoM, we measured
Caspase-3 activity in HUVEC after 24 h of serum/GF
deprivation. Caspase-3 activity in cultures treated with
HDL+ApoM upon serum/GF deprivation was significantly
lower than in cultures treated with HDL-ApoM or without
HDL (Fig. 1e). Next, we investigated whether the anti-
apoptotic effect of HDL+ApoM could also be achieved after
a short serum/GF deprivation time. Therefore, we quanti-
fied Caspase-3 activity 2 h after the removal of serum and
growth factors and found a reduction of Caspase-3 activity
in lysates from HDL+ApoM treated cells, whereas HDL-
ApoM treatment did not confer protection against serum/
GF deprivation induced cell-death (Fig. 1f).
Since the HDL+ApoM treatment of HUVECs is anti-
apoptotic, it is expected to have higher cell viability in
those cultures. We verified this hypothesis by using the
MTT assay. Serum/GF deprivation reduced HUVEC via-
bility, but this reduction was significantly mitigated by
HDL+ApoM. In contrast, HDL-ApoM did not improve cell
viability either after 24 h or after 48 h of serum/GF
deprivation (Fig. 2a). Next, we investigated which con-
centration of HDL+ApoM was required to promote cell
viability upon serum/GF deprivation. Interestingly, HDL
+ApoM at 50 μg/ml and 25 μg/ml significantly increased
cell viability when compared to HDL-ApoM and non-
HDL treatments, whereas HDL+ApoM at 10 μg/ml only
significantly increased cell-viability when compared to
non-HDL treatment (Fig. 2b).
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Thus, we conclude that the HDL anti-apoptotic effect
in serum/GF deprived endothelial cells is primary medi-
ated by HDL containing ApoM and S1P.
S1P1 and S1P3 activation mediate the protective effect of
ApoM-associated HDL
S1P signals through five different G-couple protein re-
ceptors known as S1P1-5. Thus, to understand the anti-
apoptotic role of HDL+ApoM in the endothelium, we
studied the expression of S1PR in HUVEC by qPCR. We
found that HUVEC express S1P1 and S1P3, but do not
express S1P2, S1P4 or S1P5 (Fig. 3a). Since S1P2 expres-
sion in HUVEC has been reported previously [24], we
simultaneously run a qPCR using HEK293 cDNA as a
positive control of S1P2 expression to assure the correct
performance of S1P2 probe (data not shown). Then, we
examined which S1P receptor/s are responsible for HDL
+ApoM anti-apoptotic function. For that purpose, we
followed a pharmacological approach and used receptor-
specific agonists to mimic S1P stimulation. SEW2871, an
S1P1 specific agonist, and CYM5541, an S1P3 specific
agonist, reduced the amount of apoptotic endothelial
cells upon serum/GF deprivation (Fig. 3b and c respect-
ively). We also tested the S1P2 specific agonist ML-031.
Nevertheless, ML-031 did not confer any protection
against apoptosis (Fig. 3d). Next, we investigated if sim-
ultaneous pharmacological activation of S1P1 and S1P3
could confer a greater protection against serum/GF
Fig. 1 HDL containing ApoM protects endothelial cells against serum/GF deprivation-induced cell death. a HUVEC were grown to confluence in
full medium and then switched to serum starvation medium or serum/GF deprivation medium. The graph represents the percentage of apoptotic
cells (Annexin V+ and 7-ADD−) identified by flow cytometry. Error bars correspond to SEM of n = 5. One-way ANOVA p < 0.001 followed by Holm-Sidak
method multiple-comparison post hoc test. b–d Cells were serum/GF deprived and treated with ± HDL+ApoM 50 μg/ml or HDL-ApoM 50 μg/ml in b and
c and ± Total HDL 500 μg/ml or HDL-ApoM 500 μg/ml in d for 18 h and then analyzed by flow cytometry. Error bars correspond to SEM. c shows dot
plots from a representative experiment of B. In b, n = 4, one-way ANOVA p = 0.001 followed by Holm-Sidak method multiple-comparison post hoc test.
In d, n = 10, ANOVA on ranks p = 0.016 followed by SNK method multiple-comparison post hoc test. e-f Measurements of Caspase-3 activity in HUVEC
lysates. Cells were incubated in serum/GF starvation medium with ± HDL+ApoM 25 μg/ml, HDL-ApoM 25 μg/ml for 24 h in e and for 2 h in f. Data were
normalized versus serum/GF starvation condition and error bars correspond to SEM. In E, n = 4, ANOVA on ranks p = 0.006 followed by SNK method
multiple-comparison post hoc test. In F, n = 3, one-way ANOVA p = 0.012 followed by Holm-Sidak method multiple-comparison post hoc test. *p < 0.05
Ruiz et al. Lipids in Health and Disease  (2017) 16:36 Page 4 of 12
deprivation. However, the percentage of apoptotic cells
treated with both, SEW2871 and CYM5541, is compar-
able to the cells only treated with SEW2871 or
CYM5541 (Fig. 3e).
To confirm the participation of S1P1 and S1P3 in
HDL containing ApoM protection against serum/GF
deprivation, we used S1P1 and S1P3 specific antagonists.
Blockage of S1P1 with W146 abolished the anti-
apoptotic effect of total HDL or HDL+ApoM in serum/GF
deprived HUVEC (Fig. 4a and b, respectively). Addition-
ally, W146 also abrogated the increment of viability
caused by HDL+ApoM in serum/GF deprived HUVEC
(Fig. 4c). Likewise, blockage of S1P3 with CAY10444
abolished the anti-apoptotic effect of total HDL in
serum/GF deprived HUVEC (Fig. 4d).
In conclusion, HDL required S1P1 and S1P3 signaling
to achieve their anti-apoptotic effect in serum/GF de-
prived HUVEC. However, pharmacological activation of
S1P1 or S1P3 was sufficient to mimic HDL protection.
ApoM-bound S1P confers longer protection to
endothelial cells against serum/GF deprivation
Plasma S1P is mostly carried by ApoM in HDL, but a
fraction is bound to albumin [7]. Therefore, we
elucidated if albumin-bound S1P could also protect
endothelial cells against serum/GF deprivation in-
duced cell-death. In order to have a direct compari-
son between ApoM-bound S1P and albumin-bound
S1P, we produced soluble recombinant human ApoM in
E. coli and loaded it with S1P. Previous work has studied
S1P in apoptosis by directly adding S1P as a free molecule
to the cell medium (for instance [9, 25–27]). Therefore,
we also included free S1P in our study. First, as a visual
approximation, we performed a DNA fragmentation
assay. Endothelial cells were serum/GF deprived for
24 h in the presence of free S1P, ApoM, ApoM-
bound S1P or albumin-S1P. Interestingly, ApoM-
bound S1P treated cells showed a lower level of DNA
fragmentation than free S1P or albumin-bound S1P
treated cells (Fig. 5a). To confirm this result we car-
ried out Caspase-3 activity assays. Importantly, free
S1P, ApoM-bound S1P and albumin-bound S1P de-
creased Caspase-3 activity after 24 h of serum/GF
deprivation (Fig. 5b). However, ApoM-bound S1P and
albumin-bound S1P did it more efficiently than free
S1P. Remarkably, when we looked at more prolonged
protection, 48 h of serum/GF deprivation, only
ApoM-bound S1P reduced Caspase-3 activity in
Fig. 2 HDL containing ApoM promotes endothelial cell viability upon serum/GF deprivation. a MTT assay of HUVEC after 24 h (left) or 48 h (right)
of incubation in serum/GF deprivation medium with or without HDL+ApoM 50 μg/ml or HDL-ApoM 50 μg/ml. Data are expressed as mean ± SD. N
= 4, one-way ANOVA p < 0.001 followed by Holm-Sidak method multiple-comparison post hoc test. b Cells were assayed as in a, but HDL+ApoM or
HDL-ApoM concentrations were 50, 25 or 10 μg/ml. Data are expressed as mean ± SD. N = 4, one-way ANOVA p < 0.001 followed by Holm-Sidak
method multiple-comparison post hoc test. * over the bars indicates statistical significance versus serum/GF deprivation treatment. *p < 0.05
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HUVEC upon serum/GF deprivation (Fig. 5c). In con-
sonance with this finding, free S1P, ApoM-bound S1P
and albumin-bound S1P treatments improved cell via-
bility upon serum/GF deprivation, but ApoM-bound
S1P was significantly more effective than free S1P
and albumin-bound S1P (Fig. 5d).
Since anti-apoptotic and pro-survival effects of S1P
were carrier dependent, we investigated if differences
can be due to particular activation of S1PR. To study
this, we performed Caspase-3 assays as in Fig. 5b, but
in the presence of the S1P1 antagonist W146 or the
S1P3 antagonist CAY10444. Interestingly, all three
alternative ways to supply S1P to endothelial cells re-
quired S1P1 and S1P3 signaling to become anti-
apoptotic (Fig. 5e and f ).
Thus, we concluded that the anti-apoptotic effect of
S1P in serum/GF deprived endothelial cells was carrier
dependent, ApoM-bound S1P being the most powerful
of all three carriers. Furthermore, anti-apoptotic activity
of S1P was mediated by S1P1 and S1P3 with independ-
ence of which S1P carrier was used.
PI3K/AKT and ERK1/2 signaling pathways are implicated
in the anti-apoptotic effect of S1P in serum/GF deprived
cells
It has been shown that the anti-apoptotic activities of
S1P and HDL are mediated by PI3K/AKT and ERK1/2
signaling pathways [15, 16, 28]. Moreover, a previous
study demonstrated that phosphorylation of AKT and
ERK is induced by HDL+ApoM and albumin-S1P, but not
by HDL-ApoM [7]. To link these antecedents, we used the
PI3K/AKT inhibitor LY249002 and the MEK inhibitors
U0126 and PD98059. We added these inhibitors to
serum/GF deprived cells in the presence of free S1P,
Fig. 3 Pharmacological activation of S1P1 or S1P3 protects endothelial cells against serum/GF deprivation-induced cell death. a Relative expression of
S1PR in HUVEC. Total RNA was analyzed by qPCR using Taqman probes for S1PR and normalized against GAPDH expression. S1P1 expression was
chosen as reference. Error bars correspond to SD, n.d., not detected. b–e HUVEC were grown up to confluence in full medium, then switched to
serum/GF deprivation medium with SEW2971 5 μM b and e, ML-031 5 μM c and e or/and CYM5541 5 μM d and e for 18 h and then analyzed by flow
cytometry. The percentage of apoptotic cells (AnnexinV+ and 7-ADD−) was normalized versus serum/GF starvation condition. Error bars correspond to
SEM. In b, n = 9, Mann-Whitney U-test p <0.001. In c, n = 7 Mann-Whitney U-test p = 0.026. In D, n = 4, Mann-Whitney U-test p = 0.343. In e, n = 5, one-
way ANOVA p = 0.004 followed by Holm-Sidak multiple-comparison post hoc test. In e, * over the bars indicates statistical significance versus serum/GF
deprivation treatment. *p < 0.05
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ApoM, ApoM-bound S1P or albumin-bound S1P. Then,
we lysed the cells and analyzed them by western-blot or
Caspase-3 activity., The phosphorylation of AKT and
ERK by free S1P, ApoM-bound S1P or albumin-S1P was
abolished when cells were treated with LY249002 or
U0126 (Fig. 6a). LY294002, U0126 and PD98059 also
canceled the inhibitory effect of free S1P, ApoM-bound
S1P or albumin-S1P on Caspase-3 activation in serum/
GF deprived HUVEC (Fig. 6b).
Next, we determined whether S1PR activation medi-
ated the phosphorylation of AKT and ERK by S1P. The
selective S1P1 antagonist W146 dramatically reduced
the phosphorylation of AKT and ERK by ApoM-bound
S1P and albumin-bound S1P. However, when S1P was
added as a free molecule, W146 decreased ERK phos-
phorylation but surprisingly not AKT phosphorylation.
In contrast, CAY10444 reduced the phosphorylation of
AKT and ERK mediated by free S1P, ApoM-bound S1P
and albumin-S1P (Fig. 7a and b).
In conclusion, S1P anti-apoptotic effect on serum/
GF deprived endothelial cells went via S1P1 and S1P3
and required the phosphorylation of AKT and ERK1/2
(Additional file 1: Fig. S1).
Discussion
Previous studies have pointed out the protective role of
HDL on endothelial cells upon different cell-death stim-
uli, including oxidized LDL [29, 30] and serum/GF
Fig. 4 S1P1 and S1P3 activation mediates the protective effect of ApoM-associated HDL in human endothelium. a-d Cells were pre-incubated
with ± W146 1 μM or CAY10444 5 μM in serum/GF starvation medium for 30 min. a HUVEC were incubated in serum/GF starvation medium with
total HDL 500 μg/ml and W146 1 μM for 18 h and AnnexinV+ and 7-ADD− cells were quantified by flow cytometry. As control, the experiment
was replicated without W146. Error bars indicated SEM of n = 4, Mann-Whitney U-test p = 0.029 when W146 was absent and Mann-Whitney U-test
p = 0.343 in W146 presence. b Cells were treated with HDL+ApoM 25 μg/ml plus W146 1 μM for for 2 h and then lysated and Caspase-3 activity
measured. Data are represented as the mean ± SEM of n = 2–6. Student t-test p = 0.010 when W146 was not added; Student t-test p = 0.388 in
W146 presence. c Cell viability was assayed by MTT. Cells were switched to serum/GF starvation medium with ± HDL+ApoM 25 μg/ml, HDL-ApoM 25
μg/ml and ±W146 1 μM for 24 h. Error bars represent SD of n = 3. Control condition (no W146) data were analyzed by one-way ANOVA p = 0.004
followed by Holm-Sidak method multiple-comparison post hoc test. W146 condition data were analyzed by ANOVA on ranks p = 0.059. d Cells
were assayed as in A, but using CAY10444 5 μM instead of W146. Error bars indicated SEM of n = 4-5, Mann-Whitney U-test, p = 0.029 when
CAY10444 was not present: Mann-Whitney U-test p = 0.690 in CAY10444 presence. *p < 0.05
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deprivation [15, 16]. Likewise, anti-apoptotic properties of
free S1P have been demonstrated [9, 25–27, 30, 31]. Here
we connect previous findings and show that ApoM-
containing HDL, and therefore S1P, have anti-apoptotic
and pro-survival properties in serum/GF deprived endo-
thelial cells (Figs. 1 and 2). Importantly, S1P also promotes
survival in cardiomyocytes [32], macrophages [31] and
other cell types [33–36]. Now, it would be relevant to
study S1P protection in other human cell types taking in
account ApoM. It is important to highlight that HDL par-
ticles are highly heterogenic in protein and lipid compos-
ition and additional cytoprotective mechanisms are
possible [37]. Which ones are relevant may depend on the
cell-death stimulus, time and concentration used.
Fig. 5 ApoM-bound S1P confers longer protection to endothelial cells against serum/GF deprivation. a–e Cells were treated with free S1P 1 μM,
ApoM 1 μM, ApoM-bound S1P 1 μM or albumin-bound S1P 1 μM. a Cells were treated for 24 h and then a cell fragmentation assay performed. b
Cells were treated for 2 h and then the Caspase 3 activity measured. ANOVA on ranks p < 0.001 followed by SNK multiple-comparison post hoc
test. c As b, but 24 h treatment. ANOVA on ranks p = 0.007 followed by SNK multiple-comparison post hoc test. d Cell viability was determined by MTT
after 24 h of treatment. Error bars correspond to SD. N = 4-5. One-way ANOVA p < 0.001 followed by Holm-Sidak method multiple-comparison post
hoc test. e-f Cells were pre-incubated with ±W146 1 μM or CAY10444 10 μM in serum/GF deprivation medium for 30 min. and then treated as in c,
but with the addition of W146 1 μM in e and CAY10444 10 μM in F. In E, n = 3, data were analyzed by one-way ANOVA p = 0.003 followed by Holm-
Sidak method multiple-comparison post hoc test and in F, n = 3, by One-way ANOVA p < 0.001 followed by Holm-Sidak method multiple-comparison
post hoc test. * over the bars indicates statistical significance versus serum/GF starvation treatment. *p < 0.05
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de Souza et al. [29] isolated HDL subpopulations and
found that small and dense HDL3, which are enriched in
S1P [and ApoM, [38]], have cytoprotective activity su-
perior to that of large and light HDL2. Interestingly,
reconstituted HDL (rHDL) with added S1P did not en-
hance the anti-apoptotic effect achieved by rHDL with-
out S1P [29]. Similarly, S1P-fortified HDL subfractions
did not to significantly improve the anti-apoptotic effect
of non-S1P-fortified HDL. Both scenarios could be ex-
plained by the fact that the exogenous S1P was not
bound to ApoM and therefore may not properly interact
with S1PR. This explanation concurs with Fig. 5a-d,
where ApoM-S1P displayed significantly elevated anti-
apoptotic activity as compared to free S1P or albumin-
S1P. In agreement, apoptosis was not inhibited when
albumin-S1P was used at 1–100 nM [29]. Likewise,
rHDL anti-apoptotic ability is enhanced when plasmalo-
gens are incorporated to rHDL [39], but the molecular
mechanism behind has not been described yet. Several
endothelial cell types express ApoM [40] and the S1P
transporter Spns2 [41]. Possibly, rHDL including plas-
malogens are better acceptors for ApoM and S1P than
plasmalogen-free rHDL.
Riwanto et al. [42] demonstrated that ApoJ enhances
HDL anti-apoptotic effect on endothelial cells. However,
ApoJ is absent in our HDL+ApoM preparations [17] and,
therefore, ApoM-S1P anti-apoptotic effect cannot be as-
cribed to ApoJ. In contrast, HDL anti-apoptotic activity
is impaired in HDL enriched in ApoC-III [42], which it
is less abundant in HDL+ApoM than in HDL-ApoM [17].
Thus, the poor anti-apoptotic capacity of ApoC-III con-
taining HDL can be explained by the low content in
ApoM-S1P.
Endothelial-cell survival is enhanced by free S1P via
S1P1 and S1P3 [19]. We corroborated this finding and
demonstrated that parallel activation of both S1P1
and S1P3 by HDL+ApoM is required to achieve S1P
anti-apoptotic and pro-survival effects (Figs. 4 and 5). Fur-
thermore, we show that S1P1 and S1P3 activation require-
ment is independent of the S1P carrier (Fig. 5e-f).
However, activation by ApoM-S1P renders a longer pro-
tection than albumin-S1P. These apparently conflicting
data can be explained by S1P carrier specific degradation
of S1P1 [43, 44]. Following activation of S1P1 by albumin-
S1P, S1P1 is internalized and degraded by the proteasome,
whereas S1P1 is internalized and recycled to the plasma
Fig. 6 AKT or ERK inhibition blocks S1P anti-apoptotic effect. a-b Cells were pre-incubated with ±W146 1 μM, CAY10444 10 μM, LY294002 50 μM,
U0126 50 μM or PD98050 50 μM for 30 min and then treated with free S1P 1 μM, ApoM 1 μM, ApoM-bound S1P 1 μM or albumin-bound S1P
1 μM for 10 min in a or 2 h in b. In a, western blots to analyze the phosphorylation of AKT and ERK induced by the treatments mentioned above.
Total AKT, ERK and GAPDH were analyzed as controls. In B, Caspase-3 activity in cell lysates after the different treatments indicated above. Data
are expressed as mean ± SEM of n = 3–6. No inhibitor set: ANOVA on ranks p < 0.001 followed by SNK method multiple-comparison post hoc test.
LY294002 set: one-way ANOVA p = 0.010 followed by Holm-Sidak method multiple-comparison post hoc test. U0126 set: ANOVA on ranks p =
0.018 followed by Dunn’s method multiple-comparison post hoc test. PD98050 set: one-way ANOVA p < 0.001 followed by Holm-Sidak method
multiple-comparison post hoc test. *p < 0.05
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membrane after ApoM-S1P activation. Unfortunately, no
data on S1P-carrier dependent biology of S1P3 are avail-
able. However, an analogous situation to S1P1 may be
plausible for S1P3.
Beyond S1PR, other plasma membrane receptors con-
nect apoptosis, HDL and its major component, ApoA1.
First, HDL3 acts via Scavenger Receptor Class B Type I
(SR-BI) to inhibit apoptosis on endothelial cells [45]. In-
deed, Li et al. [46] over-expressed SR-BI in CHO cells
and elaborated an attractive model in which SR-BI is a
pro-apoptotic receptor in absence of HDL. This model
needs to be validated in endothelial cells, but the fact
that HDL+ApoM are more efficient than HDL-ApoM in
stimulating cholesterol efflux suggests that HDL+ApoM
may have higher affinity for SR-BI than in HDL-ApoM.
Additionally, stimulation of F1-ATPase by lipid-free
ApoA1 inhibits endothelial cell apoptosis [45], but inter-
actions between HDL and F1-ATPase have not been
reported.
AKT and ERK1/2 phosphorylation mediate HDL and
S1P cytoprotective actions [15, 16, 27, 28]. Moreover,
HDL+ApoM and albumin-S1P, but not HDL-ApoM,
phosphorylate AKT and ERK [7]. Here, we confirmed
S1P-dependent phosphorylation of ERK and AKT and
demonstrated that blockage of AKT and ERK signal-
ing abolishes S1P anti-apoptotic effects (Fig. 6).
Fig. 7 S1P1 or S1P3 antagonists block AKT and ERK phosphorylation. a Cells were pre-incubated with ±W146 1 μM or CAY10444 10 μM for 30 min
and then treated with free S1P 1 μM, ApoM 1 μM, ApoM-bound S1P 1 μM or albumin-bound S1P 1 μM for 10 min. Then, cells were lysed and analyzed
by western blot for pAKT and pERK. Total AKT, ERK and GAPDH were analyzed as controls. b Quantification of relevant pairs of A. Student t-test of n =
3 independent experiments. Error bars correspond to SD. *p < 0.05
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Importantly, activation of S1P1 and S1P3 by ApoM-
S1P or albumin-S1P phosphorylate AKT and ERK
(Fig. 7). Interestingly, S1P induces AKT activation and
protects against ischemia/reperfusion in mouse cardi-
omyocytes via S1P2 and S1P3 [47, 48]. This suggests
that the pattern of S1PR activated by S1P to achieved
cytoprotection may be tissue/organism dependent.
Retinol binding protein (RBP) is another member of
the Lipocalin family and transports retinol in plasma.
Interestingly, apo-RBP is pro-apoptotic, whereas holo-
RBP is anti-apoptotic [49]. We did not identify any pro-
apoptotic activity of apo-ApoM per se in endothelial cells.
However, ApoM over-expression promotes apoptosis in
the human hepatoma derived cell line HepG2 [50]. More-
over, two other plasma Lipocalins: Lipocalin-type prosta-
glandin D2 synthase (L-PGDS) and Apolipoprotein D
(ApoD) mitigate cell-death and promote viability [51, 52].
Interestingly, ApoM and ApoD are HDL enriched in
HDL3 [38]. Thus, abundance of Lipocalins in HDL3 could
explain the high cytoprotective ability of HDL3.
Conclusions
Taken together, our results demonstrate that the HDL/
ApoM/S1P-complex plays an essential role in vascular
biology and protects endothelial cells from apoptosis.
This is especially relevant in pathologies where endothe-
lial cell apoptosis is altered such as in thrombosis and
atherosclerosis.
Additional file
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effect of ApoM-bound S1P in endothelial cells. (PPTX 631 kb)
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